A Real‐World Study of Tafasitamab for the Treatment of Relapsed or Refractory Diffuse Large B‐Cell Lymphoma in the United States

ABSTRACT Background Tafasitamab, a CD19‐targeting immunotherapy, is approved in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B‐cell lymphoma (R/R DLBCL) ineligible for autologous stem cell transplant. This real‐world study describes patient characteristics, treatment patterns, and outcomes associated with tafasitamab for R/R DLBCL across US practice settings. Methods A retrospective physician‐abstracted chart review was conducted among US adults initiating tafasitamab (with/without lenalidomide) for R/R DLBCL as part of routine clinical care. Data were summarized using descriptive statistics. Cox proportional hazards‐based analyses were performed to determine baseline characteristics associated with real‐world progression‐free survival and overall survival. Results Twenty‐three physicians (83% community physicians) provided data on 181 patients (64% White; median follow‐up since initiation, 14.7 months) meeting eligibility criteria. Most patients (72%) received tafasitamab as second‐line (2L) therapy. Real‐world overall response rate (95% CI) to tafasitamab was 73.5% (67.0–79.9). Median (95% CI) real‐world progression‐free survival and overall survival from tafasitamab initiation were 11.3 (9.8–13.6) and 24.8 (17.8–NE) months, respectively. In multivariable Cox proportional hazards‐based analyses, tafasitamab use in third‐line to fifth‐line (3L–5L) (vs. 2L), bulky disease (vs. non‐bulky), Ann Arbor Stage III–IV (vs. stage I–II), and increasing Charlson Comorbidity Index scores were determined as factors associated with increased progression risk. In addition, increasing age, tafasitamab in 3L–5L (vs. 2L), bulky disease (vs. non‐bulky), and Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2 (vs. < 2) were associated with higher mortality risk. Conclusion This analysis of a diverse US population who received tafasitamab for R/R DLBCL predominantly in community practice settings supports the clinical benefit of tafasitamab. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.